Skip to main content

Table 3 Comparison between pre-treatment and post-treatment lipid profile and Lp-PLA2 in patients who achieved SVR (n = 86)

From: The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids

Lipid parameter Time Paired t-test
Pre-treatment 12 weeks post-treatment t p
LDL (mg/dl) 71.977 ± 24.126 (26–130) 103.244 ± 46.570 (44–203) −9.395 <0.001
Total cholesterol (mg/dl) 170 ± 40.344 (80–278) 195.663 ± 55.678 (92–311) −8.764 <0.001
HDL (mg/dl) 48.43 ± 6.785 (31–60) 53.907 ± 8.674 (37–71) −10.1 <0.001
Lp-PLA2 (ng/ml) 322.372 ± 79.146 (189–498) 263.791 ± 51.804 (166–412) 13.829 <0.001
  1. Abbreviations: n, number; LDL, low-density lipoprotein; HDL, high-density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2